23.75
-0.31 (-1.29%)
-0.31 (-1.29%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 327,093 |
|
|||||
News | (1) | ||||||
Day High | 24.28 | Low High |
|||||
Day Low | 23.34 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
23.43 | 23.34 | 24.28 | 23.75 | 24.06 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,823 | 327,093 | $ 23.88 | $ 7,810,248 | - | 18.69 - 35.73 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:51:39 | 10 | $ 23.75 | USD |
REGENXBIO Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.03B | 43.29M | 28.43M | $ 470.35M | $ 48.87M | 2.91 | 13.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 1.30% |
REGENXBIO News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 23.00 | 24.30 | 22.18 | 23.38 | 435,940 | 0.75 | 3.26% |
1 Month | 22.62 | 25.54 | 21.73 | 23.25 | 343,302 | 1.13 | 5.0% |
3 Months | 21.87 | 25.54 | 20.68 | 22.86 | 348,857 | 1.88 | 8.6% |
6 Months | 32.89 | 35.73 | 19.82 | 24.73 | 347,949 | -9.14 | -27.79% |
1 Year | 25.25 | 35.73 | 18.69 | 25.75 | 383,834 | -1.50 | -5.94% |
3 Years | 44.04 | 54.97 | 18.69 | 33.07 | 400,309 | -20.29 | -46.07% |
5 Years | 24.35 | 85.10 | 18.69 | 40.94 | 450,108 | -0.60 | -2.46% |
REGENXBIO Description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |